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Abstract 
We present the 16th reported case of Acute
Lymphoblastic  Leukemia  (ALL)  with  involve-
ment in the bladder. Our patient was a 22 year-
old  man  with  T-cell  ALL  with  a  mediastinal
mass. He received hyperfractionated cyclophos-
phamide, vincristine, doxorubicin, dexametha-
sone (HyperCVAD) with mediastinal radiation.
Prior to starting maintenance, he relapsed in
the bladder and marrow. He received a nelara-
bine-based  induction  regimen  and  achieved
remission. This was followed by an unrelated
11/12  HLA-matched  myeloablative  allogeneic
stem cell transplant. He is in complete remis-
sion for the past 409 days. 
Introduction
Bladder involvement in acute lymphoblastic
lymphoma/leukemia is a rare entity. Here we
present the 16th reported case of such a phe-
nomenon. Our patient relapsed in the bladder
and  is  now  doing  very  well,  one  and  a  half
years  out  from  a  myeloablative  allogeneic
transplant. 
Case Report 
Our patient was a 22 year-old white male
with  no  significant  past  medical  history.  He
was studying abroad in Hong Kong when he
began experiencing several days of back pain.
He visited a physician and a chest x-ray was
ordered. It revealed a mediastinal mass. The
patient  returned  to  California.  Soon  after
returning he began experiencing dyspnea, par-
ticularly when lying flat. He was seen by his
local  physician  who  ordered  an  excisional
biopsy of a palpable left supraclavicular lymph
node. Pathology revealed precursor T-cell acute
lymphoblastic lymphoma. A PET-CT revealed a
large anterior mediastinal mass with left supr-
aclavicular adenopathy and right pleural soft
tissue masses, all with elevated FDG activity.
There was also a large right pleural effusion.
The patient had a normal CBC at presentation
to our hospital. His WBC count was 5.5¥103/UL
with a 73.2% neutrophils and 17.1% lympho-
cytes, hemoglobin was 14.3 G/DL, and platelets
were 227¥109/UL. A bone marrow biopsy was
negative for disease with a normal male kary-
otype.  The  patient  was  then  started  on  the
HyperCVAD regimen. He completed all 8 cycles
without complications and was in remission
based on PET-CT findings. He then received
radiation therapy to the mediastinal mass. The
patient was getting ready to start maintenance
chemotherapy when he began complaining of
gross  hematuria.  A  repeat  PET-CT  was  per-
formed which revealed increased uptake in the
bladder and the bone marrow. His CBC at this
time showed a WBC count of 2.0¥103/UL with
51.3% neutrophils and 34.6% lymphocytes, a
hemoglobin  of  13.4,  and  a  platelet  count  of
144,000¥109/UL. This CBC was not appreciably
different from his last month’s CBC at comple-
tion  of  his  HyperCVAD.  A  urinalysis  around
this time revealed only a hazy clarity to the
urine,  2  RBC/high  power  field  (HPF),  1
WBC/HPF, and 2+ mucous but was otherwise
normal.  He  was  seen  by  urology  and  a  cys-
toscopy noted a bladder mass. Bone marrow
biopsy  revealed  5-10%  involvement  of  blasts
consistent  recurrent  precursor  T-cell  acute
lymphoblastic  leukemia  (Figures  1,  2).  The
flow  cytometry  identified  these  cells  as
expressing CD2, CD5 (weak), CD7, Cd10, and
TdT  with  very  weak/absent  CD8  which  was
consistent with precursor T-cell lymphoblasts.
The karyotype was 46XY. The patient returned
to his urologist who performed a biopsy on the
bladder  mass  that  was  also  morphologically
consistent  with  T-cell  acute  lymphoblastic
leukemia although immunohistologic staining
could not be performed (Figure 3). 
The  patient  received  reinduction
chemotherapy.  His  regimen  matched  a
Children’s  Oncology  Group  regimen  incorpo-
rating nelarabine (patient was off protocol due
to his age). He no longer experienced gross
hematuria after the initiation of reinduction
chemotherapy. He received therapy under this
regimen for approximately 2 months and then
proceeded  to  myeloablative  allogeneic
hematopoietic stem cell transplantation using
an  11/12  unrelated  donor.  The  conditioning
regimen included total body irradiation with a
cranial  boost,  cyclophosphamide,  and  etopo-
side. The patient tolerated the regimen well
with  no  GVHD  or  readmissions  after  his
engraftment and discharge. He is now 409 days
out  from  transplantation  and  is  without
relapse  or  complaints.  He  subsequently
returned to college where he completed his last
semester of college and received his degree. 
Discussion 
Acute lymphoblastic leukemia (ALL) is com-
posed of a heterogenous group of malignan-
cies and encompasses some of the most com-
plex treatments in cancer. Precursor T-cell ALL
is a subtype of ALL noted for its more success-
ful  long  term  outcome  in  adults  when  com-
pared to B-cell ALL.1
The backbone of ALL induction regimens is
comprised of combinations of vincristine, cor-
ticosteroids,  and  anthracyclines.  Dexame  -
thasone is generally the steroid of choice due
to its high levels of penetration into the cere-
brospinal  fluid.2 Complete  remission  rates
have been reported at 72-92% with a median
remission  duration  of  18  months.3 In  our
patient,  prior  to  the  discovery  of  bladder
involvement,  a  hyper-CVAD  regimen  (hyper-
fractionated  cyclophosphamide,  vincristine,
doxorubicin, dexamethasone), which included
radiation for consolidation in patients with a
mediastinal mass, was used. This protocol was
reported by Thomas et al. as achieving a com-
plete remission (CR) in 91% of patients stud-
ied  with  lymphoblastic  lymphoma.  At  three
years, progression free survival was 66% and
overall survival was 70%.4 Our patient under-
went eight cycles of hyper-CVAD and consoli-
dation  with  radiation  and  was  scheduled  to
undergo  maintenance  therapy  prior  to  his
relapse.  An  alternative  initial  strategy  that
could have been pursued was autologous stem
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cell  transplantation  which  has  also  demon-
strated favorable long-term outcomes in T-cell
ALL. In a study by Vancouver General Hospital,
patients were given primary therapy utilizing
hematopoietic stem cell transplant. This strat-
egy  incorporated  intensive  therapy,  which
combined  features  of  non-Hodgkin’s  lym-
phoma and ALL treatment. 
This was then followed by high dose consol-
idation therapy. In their study, the four year
event free survival was 69% in those patients
who received autografts. Some patients with
bone marrow involvement and/or younger age
proceeded to allogeneic transplant and did not
demonstrate disease relapse at 38-141 months
since time of diagnosis.5
Current  therapies  for  T-cell  ALL  produce
high responses, but not approximately one half
of patients will relapse within 2 years.6 Our
patient unfortunately relapsed just prior to his
maintenance  therapy.  His  initial  salvage
chemotherapy incorporated nelarabine in his
regimen.  This  regimen  was  based  on  the
Children’s  Oncology  Group  (COG)  protocol
AALL0434.  In  this  protocol,  the  Berlin-
Frankfurt-Munster (BFM) chemotherapy com-
bination is used as the backbone for intense
combination  chemotherapy.7 Patients  may
then be randomized to nelarabine in the con-
solidation cycles. Nelarabine has been shown
to have antineoplastic activity in patients with
relapsed/refractory  T-cell  ALL.8-9 As  a  result,
nelarabine was approved by the Food and Drug
Administration  specifically  for  T-cell  leuke  -
mias.10 The  mechanism  of  action  includes
incorporation of ara-G, which is a deoxyguano-
sine  analogue  and  the  active  metabolite  of
nelarabine,  into  the  deoxyribonucleic  acid
(DNA) of leukemic blasts. This accumulation
leads to inhibition of DNA synthesis and cell
death. In the study by DeAngelo et al. from the
Cancer  and  Leukemia  Group  B,  nelarabine
demonstrated complete remission rates of 31%
with minimal toxicities in relapsed/refractory
ALL patients even as a single agent.11 Current
ongoing  clinical  trials  are  now  evaluating
nelarabine as a frontline agent in newly diag-
nosed ALL such as the above referenced COG
study.12
Our  patient  had  a  rare  presentation  of
relapse appearing in the bladder. In our review
of the literature, only 15 such cases had been
previously reported.13Interestingly, gross hema-
turia as a presentation of acute leukemia is also
quite rare as noted by the paucity of cases in the
literature.14,15 Our  patient’s  PET  findings
revealed  uptake  suspicious  in  the  bladder
whereas the kidneys’ appearance on PET was
more in line with physiologic uptake. However,
ALL is known to more commonly relapse in the
kidneys, and we propose that seeding into the
bladder was a possible mechanism.16,17 The kid-
neys may act as a reservoir for leukemic cells
even  in  a  patient  thought  to  be  in  complete
remission.18 In an autopsy study performed at
the National Institute of Health, it was noted
that patients with leukemia thought to be in
remission  in  the  marrow  actually  had  occult
involvement in the kidneys.19The authors noted
that  leukemic  cell  infiltrates  were  found  at
autopsy  in  the  tissues  of  10  of  15  acute
leukemia patients dying during complete bone
marrow remission and noted the kidneys as the
most  common  site  of  leukemic  infiltrate  in
deceased leukemia patients. In such cases of
bladder involvement, tsre did not appear to be a
standard of therapy.13 Our patient’s T cell ALL
was  clearly  behaving  aggressively,  having
relapsed in the marrow and bladder subsequent
to chemotherapy and the decision was made to
treat  him  as  aggressively  as  possible  with  a
myeloablative  allogeneic  stem  cell  transplant.
He is now doing well over one year out from
transplantation.
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